Antiplatelet Activity of Clopidogrel in Coronary Artery Bypass Graft Surgery Patients

Summary

Clopidogrel is a recently introduced platelet ADP receptor antagonist, belonging to the thienopyridine derivatives, like its analogue ticlopidine. Its potential advantage is to be safer than ticlopidine. At 75 mg/od clopidogrel significantly inhibits platelet aggregation in ambulatory patients with symptomatic atherosclerotic disease and it prevents the recurrence of ischemic events more efficiently than aspirin. Its adequate dose in more acute situations remained to be determined. Therefore, sixty two patients with coronary artery disease were randomly assigned in four groups treated, within 24 h after coronary artery bypass graft, by clopidogrel 50 mg/od, 75 mg/od or 100 mg/od or by ticlopidine 250 mg/bid which was considered as the reference. The tolerance of clopidogrel was fairly good during the whole period of the study. Bleeding time and ex-vivo platelet aggregation induced by ADP 2 μM and 5 μM were performed at day -1, +9 and +28 after surgery. Like ticlopidine, the three dose levels of clopidogrel significantly inhibited ex-vivo platelet activity and prolonged the bleeding time at day 28. However, unlike ticlopidine, the inhibitory effects of clopidogrel were not significant at day 9, especially with 75 mg/od, a dose which was found to significantly protect patients in a chronic situation. Hence, although the clinical outcome for patients included in this limited study was the same in the four groups, these results suggest that the dose regime of clopidogrel should be more extensively investigated during the early period following coronary artery bypass graft, facing an overproduction of young and hyperreactive platelets. By analogy, the dose regime should be also investigated in other situations with an acute risk of arterial thrombotic occlusion.

Keywords

Platelets - clopidogrel - CABG surgery

• References

• 1 Schror K. The basic pharmacology of ticlopidine ans clopidogrel. Platelets 1993; 4: 252-61.
• 2 Coukell AJ, Markham A. Clopidogrel. Drugs 1997; 5: 745-50.
• 3 Mills DCB, Puri R, Hu CJ, Minniti C, Grana G, Freedman MD, Colman RF, Colman RW. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992; 12: 430-36.
• 4 Savi P, Laplace MC, Maffrand JP, Herbert JM. Binding of [3H]-2 methylthio ADP to rat platelets. Effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 1994; 269: 772-7.
• 5 Savi P, Heilmann E, Nurden P, Laplace MC, Bihour C, Kieffer G, Nurden AT, Herbert JM. Clopidogrel: An antithrombotic drug acting on the ADP-dependent activation pathway of human platelets. Appl Thromb Hemost 1996; 2: 35-42.
• 6 Gachet G, Savi P, Ohlmann P, Maffrand JP, Jakobs KH, Cazenave JP. ADP receptor induced activation of guanine nucleotide binding proteins in rat platelet membranes an effect selectively blocked by the thienopyridine clopidogrel. Thromb Haemost 1992; 68: 79-83.
• 7 Herbert JM, Frehel D, Vallee E, Kieffer G, Gouy D, Berger Y, Necciari J, Defreyn G, Maffrand JP. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 11: 180-98.
• 8 Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998; 129: 394-405.
• 9 Savi P, Nurden A, Nurden AT, Levy-Toledano S, Herbert JM. Clopidogrel: a review of its mechanism of action. Platelets 1998; 9: 251-5.
• 10 Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J, Defreyn G, Maffrand JP. Importance of hepatic metabolism in the anti-aggregating activity of the thienopyridine clopidogrel. Biochem PharmacoI 1992; 44: 527-32.
• 11 Savi P, Combalbert J, Gaich C, Rouchon MC, Maffrand JP, Berger Y. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994; 72: 313-7.
• 12 Kieffer G, Caplain H, Thiercelin JF, Thebault JJ. Tolerance and pharmacological activity of a new antiplatelet agent clopidogrel (SR 25990 C) in normal healthy volunteers after single increasing administrations. Thromb Haemost 1989; 62: 411 (abstr).
• 13 Caplain H, Kieffer G, Thiercelin JF, Thebault JJ. Tolerance and clinical pharmacology of repeated administration of clopidogrel (SR 25990 C) a new antiplatelet agent, at three dose levels in normal healthy volunteers. Thromb Haemost 1989; 62: 410 (abstr).
• 14 Samama Ch M, Bonnin Ph, Bonneau M, Pignaud G, Mazoyer E, Bailliart O, Maffrand P, Viars P, Caen JP, Drouet LO. Comparative arteriaI antithrombotic activity of clopidogrel and acetyl salicylic acid in the pig. Thromb Haemost 1992; 68: 500-5.
• 15 Herbert JM, Dol F, Bernat A, Falotico R, Lalé A, Savi P. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost 1998; 80: 512-8.
• 16 Boneu B, Destelle G. Platelet antiaggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996; 76: 939-43.
• 17 CAPRlE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
• 18 David JL, Montfort F, Hérion F, Raskinet R. Compared effects of three dose levels of ticlopidine on platelet functions in normal subjects. Thromb Res 1979; 14: 35-9.
• 19 Chevigné M, David JL, Rigo P, Limet R. Effect of ticlopidine on saphenous vein bypass patency rates: a double-blind study. Ann Thorac Surg 84 37: 371-8.
• 20 Limet R, David JL, Magotteaux P, Larock MP, Rigo P. Prevention of aorto-coronary bypass graft occlusion: beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. J Thorac Cadiovasc Surg 1987; 94: 773-83.
• 21 Dixon WJ. (ed). BMP Statistical software. University of California Press: 1988
• 22 Becquemin JP. for the “Etude de la Ticlopidine après Pontage Fémoro-Poplité and the Association Universitaire de Recherche en Chirurgie”. Effect of ticlopidine on the long term patency of saphenous-vein bypass grafts in legs. N Engl J Med 1997; 337: 1728-31.
• 23 Rinder CS, Bohnert J, Rinder HM, Mitchell J, Ault K, Hillmann R. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology 1991; 75: 388-93.
• 24 David JL, Zicot M, Thiercelin JF, Maffrand JP, Kieffer G. Platelet response to treatment by SR 25990 C (Clopidogrel) in chronic arteritic patients. Fibrinolysis 1990; 4: 59 (abstr).
• 25 Bachmann F, Savcic M, Hauert J, Geudelin B, Kieffer G, Cario R. Rapid onset of inhibition of ADP-induced platelet aggregation by a loading dose of clopidogrel. Eur Heart J 1996; 17: 263 (abstr).
• 26 Savcic M, Goy JL, Shapira M, Kappenberger L. Antiaggregatory efficacy and tolerance of clopidogrel in percutaneous transluminal balloon angioplasty, a pilot study. Eur Heart J 1995; 16: 417 (abstr).
• 27 Yao S-K, Ober J, Ferguson JJ, Maffrand JP, Anderson HV, Buja LM, Willerson JT. Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol 1994; 267: H 488-93.
• 28 Janzon L, Bergqvist D, Boberg J, Boberg M, Eriksson I, Lindgarde F, Persson G. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicenter Study. J Int Med 1990; 227: 301-8.